Axsome Therapeutics Inc (AXSM) Just Recorded A Sigfniciant Increase

September 17, 2017 - By Stephen Andrade

The stock of Axsome Therapeutics Inc (NASDAQ:AXSM) is a huge mover today! The stock increased 4.21% or $0.2 on September 15, reaching $4.95. About 104,839 shares traded. Axsome Therapeutics Inc (NASDAQ:AXSM) has declined 59.08% since September 17, 2016 and is downtrending. It has underperformed by 75.78% the S&P500.
The move comes after 5 months positive chart setup for the $116.87 million company. It was reported on Sep, 17 by Barchart.com. We have $5.10 PT which if reached, will make NASDAQ:AXSM worth $3.51 million more.

Axsome Therapeutics Inc (NASDAQ:AXSM) Ratings Coverage

Among 3 analysts covering Axsome Therapeutics (NASDAQ:AXSM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Axsome Therapeutics had 3 analyst reports since December 14, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, December 15 by Cantor Fitzgerald. Brean Capital initiated it with “Buy” rating and $20 target in Monday, October 3 report. The stock of Axsome Therapeutics Inc (NASDAQ:AXSM) earned “Buy” rating by Ladenburg Thalmann on Monday, December 14.

More notable recent Axsome Therapeutics Inc (NASDAQ:AXSM) news were published by: Globenewswire.com which released: “Axsome Therapeutics Appoints World Leading Experts to Depression Scientific …” on March 19, 2015, also Seekingalpha.com with their article: “An Analysis Of Axsome Therapeutics’ Upcoming Catalysts” published on May 25, 2017, Seekingalpha.com published: “Axsome Therapeutics Sweetens The Deal For Investors” on August 29, 2017. More interesting news about Axsome Therapeutics Inc (NASDAQ:AXSM) were released by: Globenewswire.com and their article: “Axsome Therapeutics Reports Third Quarter 2016 Financial Results” published on November 14, 2016 as well as Globenewswire.com‘s news article titled: “Axsome Therapeutics Appoints John Golubieski as Chief Financial Officer” with publication date: July 06, 2017.

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $116.87 million. The Firm is engaged in developing therapies for the management of central nervous system disorders, including pain. It currently has negative earnings. It operates in the business of developing novel therapies for the management of CNS disorders segment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.